On June 16, 2017, 107,330,210 Idorsia shares were listed on SIX. Furthermore, shares issued through the conversion of the first tranche of the convertible loan provided by Cilag Holding AG, an indirect subsidiary of Johnson & Johnson (CHF 135.4 million converting into 11,793,220 Idorsia shares (“Authorized Shares”) were listed on June 20, 2017.
On July 13, 2018 the Group privately placed 11,912,000 new registered shares of CHF 0.05 par value from existing authorized capital at CHF 25.62 per new share receiving gross proceeds of CHF 305 million through an accelerated book-building process. Concurrently to the private placement of new shares, the Group issued CHF 200 million of senior unsecured convertible bonds (“the Bonds”) on July 17, 2018. The Bonds mature on July 17, 2024 and are convertible into 5.9 million registered shares of the Group.
On May 20, 2020, the Group privately placed 11 million new registered shares of CHF 0.05 par value from existing authorized share capital at CHF 30 per new share receiving gross proceeds of CHF 330 million, by way of an accelerated book-building process.
On October 22, 2020, the Group issued 23.8 million new registered shares from existing authorized share capital at CHF 22.50 per new share receiving gross proceeds of CHF 535.5 million through an at-market rights offering. As a result of the capital increase, the share capital of Idorsia registered in the commercial register was increased from CHF 7,132,337.30 to CHF 8,322,337.30 divided into 166,446,746 registered shares with a nominal value of CHF 0.05 each.
Idorsia Ltd is part of the following indices: SPI, SPIEX, SXSLI, SXI Life Sciences, SXI Bio+Medtech, and SSIRT.
Idorsia is traded under the following symbols: Reuters IDIA.S / Bloomberg IDIA:SW.